CoChat

A Paradigm Shift: Arrhythmogenic Cardiomyopathy Is an Inflammatory Disease

Open access

The DOI matches its Crossref record; 125 of the 125 references it cites were found in a registry or an index; 160 of the 216 sources its claims cite were checked for support.

Abstract

Arrhythmogenic cardiomyopathy (ACM) is a genetic myocardial disorder marked by progressive cardiomyocyte loss, fibro-fatty replacement, ventricular arrhythmias, and risk of sudden cardiac death. Traditionally considered a structural and electrical disease driven by desmosomal dysfunction, emerging evidence redefines ACM as an inflammatory cardiomyopathy in which immune activation plays a central role. This review integrates genetic, molecular, experimental, and clinical data to highlight inflammation as a unifying feature of ACM. Desmosomal gene variants impair cell adhesion and also activate cardiomyocyte-intrinsic inflammatory pathways, including nuclear factor of kappa B (NFκB) and glycogen synthase kinase 3β (GSK3β) signaling, promoting cytokine release, immune cell recruitment, and fibrotic remodeling. Preclinical studies suggest inflammation precedes structural changes, indicating it may be an initiating event rather than a secondary response. Clinical and pathological findings support this model, with inflammatory infiltrates, circulating cytokines, and autoantibodies observed across disease stages. These processes often present as episodic "hot phases" resembling myocarditis, thus complicating diagnosis. The inflammatory landscape involves both innate and adaptive immunity, along with stromal and neuronal remodeling, contributing to arrhythmogenesis through gap junction disruption, calcium-handling abnormalities, and fibrosis. Environmental factors such as exercise, stress, and metabolic disturbances further modulate inflammatory pathways and disease expression. Therapeutically, this evolving perspective supports immunomodulatory approaches, including inhibition of NFκB, GSK3β, and cytokine signaling. Early clinical data on immunosuppressive and cytokine-directed therapies are promising, especially during active inflammatory phases, while gene-based strategies specifically address the underlying genetic defects. In conclusion, ACM should be recognized as an inflammatory cardiomyopathy shaped by interactions between genetic susceptibility and immune dysregulation. Integrating genetic and immunologic profiling may improve diagnosis, risk stratification, and treatment, ultimately leading to refined personalized therapeutic strategies.

Overview

CoChat Summary

## TL;DR

This narrative review argues that arrhythmogenic cardiomyopathy (ACM) should be understood as an inflammatory cardiomyopathy, not only a desmosomal structural/electrical disorder. It synthesizes clinical, pathological, experimental, and early therapeutic evidence showing that inflammation can precede remodeling and may be a treatment target.

## Key findings

  • Desmosomal gene variants account for more than 60% of patient cases, and inflammatory infiltrates are reported in 60–88% of ACM patients, especially those who died suddenly.
  • The review states that myocardial inflammation often appears as a “hot phase,” with features that can mimic myocarditis, including chest pain, recurrent troponin peaks, and LGE-MRI abnormalities; DGV-positive patients with myocarditis-like phenotypes are at increased risk of major ventricular arrhythmias and heart failure.
  • In preclinical models, inflammatory signaling is described as an early event: snRNA-seq and other multi-omic analyses showed cardiomyocyte-intrinsic NFκB activation, recruitment of CCR2+ macrophages, and inflammatory-fibrotic niche formation before extensive fibrosis.
  • Therapeutic examples reported include SB216763 improving ventricular ectopy, function, fibrosis, inflammation, normalization of ID proteins, and survival in two murine ACM models, and Tideglusib being evaluated in a Phase 2 TaRGET clinical trial.

## Methods

  • Narrative review of ACM literature integrating genetic, molecular, experimental, and clinical evidence.
  • The authors report searching PubMed for original clinical and preclinical papers using the keywords “ACM”, “inflammation” and “immunity.”
  • The review synthesizes findings from in vivo and in vitro models, human biopsies, snRNAseq, CITE-seq/CITseq, spatial transcriptomics, imaging, and interventional studies.

## Limitations

  • The paper states that myocardial inflammation is not homogeneously detected in all preclinical models and patients with ACM.
  • The authors note that several other molecular mechanisms contribute to ACM onset and progression, so inflammation is not the only pathway.
  • The text says prospective trials are still needed to formally assess the safety and efficacy of immunosuppressive and molecularly targeted therapies; this is evident from the review nature of the paper and the reliance on preclinical/early clinical evidence.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.3390/cells15100868

Cites

125 of 125 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Figure 1 Historical timeline of myocardial inflammation in ACM. Chronological overview of key milestones in the recognition and characterization of inflammation in ACM. Initial pathological observations of inflammatory infiltrates in ARVD/ACM (1980–1990) were followed by the clinical description of the “hot phase” phenotype (1990–2000) and the identification of causative DGVs (2000s). The mid-2010s brought recognition of episodic hot phases as a hallmark of desmosomal ACM, while advances in cardiac MRI and LGE-MRI enabled non-invasive detection of myocardial inflammation (2015–2018). The current era (2020s–present) is defined by active investigation of immunomodulatory therapeutic strategies.
Figure 1 Historical timeline of myocardial inflammation in ACM. Chronological overview of key milestones in the recognition and characterization of inflammation in ACM. Initial pathological observations of inflammatory infiltrates in ARVD/ACM (1980–1990) were followed by the clinical description of the “hot phase” phenotype (1990–2000) and the identification of causative DGVs (2000s). The mid-2010s brought recognition of episodic hot phases as a hallmark of desmosomal ACM, while advances in cardiac MRI and LGE-MRI enabled non-invasive detection of myocardial inflammation (2015–2018). The current era (2020s–present) is defined by active investigation of immunomodulatory therapeutic strategies.CC BY · PubMed Central
Figure 2 Stages of ACM disease progression. Five-stage model of ACM progression from concealed to clinically evident disease. Stage 1 (genetic susceptibility): DGVs disrupt intercalated disc integrity in otherwise asymptomatic individuals. Stage 2 (early inflammation): inflammatory signaling manifests as ECG abnormalities and elevated serum biomarkers. Stage 3 (immune infiltration): T lymphocyte and macrophage infiltration with initial fibrosis, presenting with chest pain and mild ventricular dysfunction. Stage 4 (fibro-fatty replacement): dense fibrotic scars and adipose infiltration drive sustained VAs and progressive ventricular dysfunction detectable by LGE on cMRI. Stage 5 (adverse electromechanical remodeling): desmosomal dysfunction-driven adipogenesis, fibrosis, and progressive electromechanical uncoupling, culminating in end-stage heart failure with biventricular dysfunction and refractory arrhythmias.
Figure 2 Stages of ACM disease progression. Five-stage model of ACM progression from concealed to clinically evident disease. Stage 1 (genetic susceptibility): DGVs disrupt intercalated disc integrity in otherwise asymptomatic individuals. Stage 2 (early inflammation): inflammatory signaling manifests as ECG abnormalities and elevated serum biomarkers. Stage 3 (immune infiltration): T lymphocyte and macrophage infiltration with initial fibrosis, presenting with chest pain and mild ventricular dysfunction. Stage 4 (fibro-fatty replacement): dense fibrotic scars and adipose infiltration drive sustained VAs and progressive ventricular dysfunction detectable by LGE on cMRI. Stage 5 (adverse electromechanical remodeling): desmosomal dysfunction-driven adipogenesis, fibrosis, and progressive electromechanical uncoupling, culminating in end-stage heart failure with biventricular dysfunction and refractory arrhythmias.CC BY · PubMed Central
Figure 3 Signaling pathways underlying ACM pathogenesis. Schematic representation of key molecular signaling cascades activated by DGVs in cardiomyocytes. Collectively, these pathways converge to produce the hallmark features of ACM: cardiac dysfunction, immune cell infiltration, fibro-fatty replacement, arrhythmias, abnormal action potentials, and cardiomyocyte death.
Figure 3 Signaling pathways underlying ACM pathogenesis. Schematic representation of key molecular signaling cascades activated by DGVs in cardiomyocytes. Collectively, these pathways converge to produce the hallmark features of ACM: cardiac dysfunction, immune cell infiltration, fibro-fatty replacement, arrhythmias, abnormal action potentials, and cardiomyocyte death.CC BY · PubMed Central
Figure 4 Therapeutic targets in ACM-associated inflammation. Overview of emerging pharmacological strategies targeting inflammatory and molecular pathways in ACM. (1) Immunosuppressives (e.g., colchicine, corticosteroids, azathioprine) reduce immune cell infiltration. (2) Anti-IL-1 therapies (e.g., anakinra, canakinumab) block IL-1 receptor signaling. (3) GSK3β inhibitors (e.g., SB216763, Tideglusib) prevent β-catenin degradation, preserving Wnt signaling. (4) NFκB inhibitors (e.g., Bay 11-7082) block Iκκ complex activation and prevent nuclear translocation of NFκB. (5) SGLT2 inhibitors (e.g., empagliflozin, dapagliflozin) exert anti-inflammatory and metabolic effects via SGLT2 and downstream pathway modulation.
Figure 4 Therapeutic targets in ACM-associated inflammation. Overview of emerging pharmacological strategies targeting inflammatory and molecular pathways in ACM. (1) Immunosuppressives (e.g., colchicine, corticosteroids, azathioprine) reduce immune cell infiltration. (2) Anti-IL-1 therapies (e.g., anakinra, canakinumab) block IL-1 receptor signaling. (3) GSK3β inhibitors (e.g., SB216763, Tideglusib) prevent β-catenin degradation, preserving Wnt signaling. (4) NFκB inhibitors (e.g., Bay 11-7082) block Iκκ complex activation and prevent nuclear translocation of NFκB. (5) SGLT2 inhibitors (e.g., empagliflozin, dapagliflozin) exert anti-inflammatory and metabolic effects via SGLT2 and downstream pathway modulation.CC BY · PubMed Central

Verification

Claims the paper makes

106 Valid · 4 Not valid · 21 Not checked · 38 Own results and interpretations

69 more claims · 41 with their cited sources checked

Create a free account to see all 169 claims and to verify the 22 references still open.

See all claims — free account
  • It may state two separate claims as one. 87
  • Probably not a substantial claim. 9
  • Borderline: one of the tests for a substantial claim is unclear. 1

Create a free account to see these claims.

Citations

Cites

Metadata

Authors
Ariyaratne, G. H. D. N., Villatore, A., Peretto, G., & Chelko, S. P.
Affiliations
  • Florida State University (US)
  • Vita-Salute San Raffaele University (IT)
Corresponding author
Chelko, Stephen P.
Venue
Cells
Publisher
MDPI AG
Published
2026-05-09
Volume
15
Issue
10
Pages
868
ISSN
2073-4409 (ISSN-L)
OpenAlex
W7162287531
Cited by
2
References
123
Citations by year
2026: 2
FWCI
2.71
Type
journal article
Language
en
Open access
Locations
  • Cells (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • PubMed Central (publishedVersion, cc-by)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
Florida Heart Research Foundation
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Effects of Exercise
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiomyopathy and Myosin Studies
  • Health Sciences › Medicine › Infectious Diseases › Viral Infections and Immunology Research
Keywords
arrhythmogenic cardiomyopathy, inflammatory cardiomyopathy, immune activation, NF-κB signaling, GSK3β signaling, cytokines, autoantibodies, myocarditis, fibrosis, gap junctions, calcium handling, sudden cardiac death, immunomodulatory therapy, genetic susceptibility
MeSH terms
Animals, Arrhythmias, Cardiac, Desmosomes, Humans, Inflammation, Cardiomyopathies, Signal Transduction, Arrhythmogenic Right Ventricular Dysplasia

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol and qwen3.8-omni-flash).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.